NLS Pharmaceutics (NLS Pharmaceutics) YoY EBITDA Growth : 65.15% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is NLS Pharmaceutics YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. NLS Pharmaceutics's YoY EBITDA Growth for the quarter that ended in Dec. 2023 was 65.15%.

NLS Pharmaceutics's EBITDA per Share for the six months ended in Dec. 2023 was $-0.12.

NLS Pharmaceutics YoY EBITDA Growth Historical Data

The historical data trend for NLS Pharmaceutics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NLS Pharmaceutics YoY EBITDA Growth Chart

NLS Pharmaceutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

YoY EBITDA Growth

Get a 7-Day Free Trial

-13.91

43.26

-347.09

16.55

62.14

NLS Pharmaceutics Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
YoY EBITDA Growth	Get a 7-Day Free Trial								-357.14	-32.76	42.71	63.35	65.15

NLS Pharmaceutics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

NLS Pharmaceutics's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (A: Dec. 2023 )
=	(EBITDA per Share (A: Dec. 2023 )	-	EBITDA per Share (A: Dec. 2022 ))	/	\| EBITDA per Share (A: Dec. 2022 ) \|
=	(-0.315	-	-0.832)	/	\| -0.832 \|
=	62.14 %

NLS Pharmaceutics's YoY EBITDA Growth for the quarter that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (Q: Dec. 2023 )
=	(EBITDA per Share (Q: Dec. 2023 )	-	EBITDA per Share (Q: Dec. 2022 ))	/	\| EBITDA per Share (Q: Dec. 2022 )) \|
=	(-0.115	-	-0.33)	/	\| -0.33 \|
=	65.15 %

NLS Pharmaceutics YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of NLS Pharmaceutics's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

NLS Pharmaceutics (NLS Pharmaceutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NLS Pharmaceutics Ltd (NAS:NLSP) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

N/A

Address

The Circle 6, Zurich, CHE, 8058

Website

https://www.nlspharma.com

NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.